Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

trisalus life sciences inc - TLSI

TLSI

Close Chg Chg %
4.18 0.06 1.44%

Closed Market

4.24

+0.06 (1.44%)

Volume: 67.57K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: trisalus life sciences inc - TLSI

TLSI Key Data

Open

$4.18

 Day Range

4.09 - 4.26

52 Week Range

3.42 - 7.95

 Market Cap

$259.94M

Shares Outstanding

61.31M

 Public Float

37.13M

Beta

0.54

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.83

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

217.48K

  

TLSI Performance

1 Week
 
 10.13%
 
1 Month
 
 -5.04%
 
3 Months
 
 -30.49%
 
1 Year
 
 -18.77%
 
5 Years
 
 N/A
 

TLSI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About trisalus life sciences inc - TLSI

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020 and is headquartered in Westminster, CO.

TLSI At a Glance

TriSalus Life Sciences, Inc.
6272 West 91st Avenue
Westminster, Colorado 80031
Phone 1-888-321-5212 Revenue 45.15M
Industry Medical Specialties Net Income -39,227,000.00
Sector Health Technology 2025 Sales Growth 53.413%
Fiscal Year-end 12 / 2026 Employees 102
View SEC Filings

TLSI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5.859
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -10.582
Enterprise Value to Sales 6.169
Total Debt to Enterprise Value 0.124

TLSI Efficiency

Revenue/Employee 442,656.863
Income Per Employee -384,578.431
Receivables Turnover 6.885
Total Asset Turnover 1.523

TLSI Liquidity

Current Ratio 2.804
Quick Ratio 2.536
Cash Ratio 1.777

TLSI Profitability

Gross Margin 84.574
Operating Margin -59.68
Pretax Margin -86.864
Net Margin -86.88
Return on Assets -132.296
Return on Equity N/A
Return on Total Capital -6,763.276
Return on Invested Capital N/A

TLSI Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 5,938.103
Total Debt to Total Assets 97.481
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 5,909.31
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Trisalus Life Sciences Inc - TLSI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- 18.51M 29.43M 45.15M
Sales Growth
- - +58.99% +53.41%
-
Cost of Goods Sold (COGS) incl D&A
- 3.29M 4.85M 6.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 715.00K 1.01M 626.00K
Depreciation
- - 697.00K 626.00K
-
Amortization of Intangibles
- - - 18.00K
-
COGS Growth
- - +47.37% +43.70%
-
Gross Income
- 15.22M 24.58M 38.19M
Gross Income Growth
- - +61.50% +55.33%
-
Gross Profit Margin
- +82.23% +83.53% +84.57%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.75M 64.05M 60.75M 65.13M
Research & Development
- 28.51M 17.69M 14.96M
Other SG&A
2.75M 35.53M 43.06M 50.17M
SGA Growth
-9.69% +2,232.20% -5.15% +7.21%
Other Operating Expense
- - - -
-
Unusual Expense
(5.84M) 10.24M (9.12M) 6.83M
EBIT after Unusual Expense
3.09M (59.07M) (27.04M) (33.77M)
Non Operating Income/Expense
3.02M 54.00K 92.00K 99.00K
Non-Operating Interest Income
3.02M 431.00K 404.00K 555.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 16.00K 3.09M 5.54M
Interest Expense Growth
- - +19,212.50% +79.42%
-
Gross Interest Expense
- 16.00K 3.09M 5.54M
Interest Capitalized
- - - -
-
Pretax Income
6.11M (59.03M) (30.04M) (39.22M)
Pretax Income Growth
+28.16% -1,066.12% +49.11% -30.56%
Pretax Margin
- -318.89% -102.07% -86.86%
Income Tax
570.85K 9.00K 6.00K 7.00K
Income Tax - Current - Domestic
1.08M 9.00K 6.00K 7.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - (513.46K)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
5.54M (59.04M) (30.05M) (39.23M)
Minority Interest Expense
- - - -
-
Net Income
5.54M (59.04M) (30.05M) (39.23M)
Net Income Growth
+16.19% -1,165.85% +49.11% -30.56%
Net Margin Growth
- -318.93% -102.09% -86.88%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
5.54M (59.04M) (30.05M) (39.23M)
Preferred Dividends
- 4.24M 3.19M 30.46M
Net Income Available to Common
5.54M (63.28M) (33.23M) (69.69M)
EPS (Basic)
0.1871 -6.7346 -1.3119 -1.8389
EPS (Basic) Growth
+22.61% -3,699.47% +80.52% -40.17%
Basic Shares Outstanding
29.61M 9.40M 25.33M 37.90M
EPS (Diluted)
0.1871 -6.7346 -1.3119 -1.8389
EPS (Diluted) Growth
+22.61% -3,699.47% +80.52% -40.17%
Diluted Shares Outstanding
29.61M 9.40M 25.33M 37.90M
EBITDA
(2.75M) (48.11M) (35.16M) (26.32M)
EBITDA Growth
+9.69% -1,651.85% +26.92% +25.14%
EBITDA Margin
- -259.89% -119.46% -58.29%

Snapshot

Average Recommendation BUY Average Target Price 10.10
Number of Ratings 5 Current Quarters Estimate -0.104
FY Report Date 06 / 2026 Current Year's Estimate -0.376
Last Quarter’s Earnings -0.15 Median PE on CY Estimate N/A
Year Ago Earnings -1.84 Next Fiscal Year Estimate -0.124
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.10 -0.07 -0.38 -0.12
High Estimates -0.07 -0.05 -0.27 0.01
Low Estimate -0.14 -0.10 -0.46 -0.26
Coefficient of Variance -25.07 -24.85 -21.16 -104.93

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Trisalus Life Sciences Inc - TLSI

Date Name Shares Transaction Value
Apr 2, 2026 David Jeffrey Matlin Director 941,944 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Mary T. Szela CEO and President; Director 317,802 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Mary T. Szela CEO and President; Director 442,802 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Mary T. Szela CEO and President; Director 742,802 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Mary T. Szela CEO and President; Director 1,578,182 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jodi Devlin Chief of Clinical Operations 100,571 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jodi Devlin Chief of Clinical Operations 463,750 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Richard B. Marshak Chief Commercial Officer 113,854 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Richard B. Marshak Chief Commercial Officer 408,937 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Bryan F. Cox Chief of Research 166,599 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Bryan F. Cox Chief of Research 261,954 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 David Patience Chief Financial Officer 265,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 David Patience Chief Financial Officer 668,899 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jennifer L. Stevens Chief Regulatory Officer 127,640 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Jennifer L. Stevens Chief Regulatory Officer 323,782 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Trisalus Life Sciences Inc in the News